Fuller P J, Matheson B A, MacDonald R J, Verity K, Clements J A
Medical Research Centre, Prince Henry's Hospital, Melbourne, Vic., Australia.
Mol Cell Endocrinol. 1988 Dec;60(2-3):225-32. doi: 10.1016/0303-7207(88)90182-7.
Anterior pituitary kallikrein-like enzyme activity, immunoreactivity and mRNA levels have previously been shown to be regulated by estrogen, in parallel with prolactin. In this study, we have examined the relationship between kallikrein and prolactin mRNA levels in estrogen-induced pituitary tumors. Treatment of Fischer 344 rats with diethylstilbestrol implants for 3, 5 and 7 weeks produced a dramatic increase in kallikrein mRNA levels and a modest increase in prolactin mRNA levels. These changes were partially reversed by bromocriptine treatment, and completely reversed by bromocriptine plus estrogen withdrawal. Using a panel of oligonucleotide probes specific for various members of the rat kallikrein gene family, we have shown that the kallikrein-like gene expressed appears to be true kallikrein.
先前已表明,垂体前叶激肽释放酶样酶活性、免疫反应性和mRNA水平受雌激素调节,与催乳素平行。在本研究中,我们检测了雌激素诱导的垂体肿瘤中激肽释放酶和催乳素mRNA水平之间的关系。用己烯雌酚植入物处理Fischer 344大鼠3、5和7周,激肽释放酶mRNA水平显著增加,催乳素mRNA水平适度增加。这些变化经溴隐亭治疗部分逆转,经溴隐亭加撤雌激素完全逆转。使用一组对大鼠激肽释放酶基因家族各成员特异的寡核苷酸探针,我们已表明所表达的激肽释放酶样基因似乎是真正的激肽释放酶。